Empagliflozin-GLP-1RA Combination Shows Cardiovascular Benefit in Diabetes
Personalized briefing
Discovery of the day · Diabetes
Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study
Dear Dr. Vijay Viswanathan, this is your personalized scientific intelligence briefing — curated for your work in Diabetes.
Key finding
Medicine · Diabetes
Discovery of the day
The EMPRISE study provides real-world evidence on the cardiovascular outcomes of combining empagliflozin with a GLP-1 receptor agonist in patients with type 2 diabetes. Researchers demonstrated that the combination therapy yielded superior cardiovascular risk reduction compared to either agent alone, as measured by major adverse cardiac events. For a clinician leading diabetes care in India where cardiovascular complications are a leading cause of morbidity, this finding supports a more aggressive dual-therapy approach to optimize outcomes in high-risk patients.
Novelty
72%
Rigor
85%
Significance
91%
Validity
82%
Clarity
78%
Advertisement
ScientificChina — The Global Marketplace for Scientific and Medical Equipments Start Browsing →
Your briefing is personalized based on your selected fields, keywords, and research interests.
